• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境细胞的CCR2是胶质瘤生物学的相关调节因子。

CCR2 of Tumor Microenvironmental Cells Is a Relevant Modulator of Glioma Biology.

作者信息

Felsenstein Matthäus, Blank Anne, Bungert Alexander D, Mueller Annett, Ghori Adnan, Kremenetskaia Irina, Rung Olga, Broggini Thomas, Turkowski Kati, Scherschinski Lea, Raggatz Jonas, Vajkoczy Peter, Brandenburg Susan

机构信息

Department of Experimental Neurosurgery Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.

Department of Neurosurgery Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany.

出版信息

Cancers (Basel). 2020 Jul 13;12(7):1882. doi: 10.3390/cancers12071882.

DOI:10.3390/cancers12071882
PMID:32668709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7408933/
Abstract

Glioblastoma multiforme (GBM) shows a high influx of tumor-associated macrophages (TAMs). The CCR2/CCL2 pathway is considered a relevant signal for the recruitment of TAMs and has been suggested as a therapeutic target in malignant gliomas. We found that TAMs of human GBM specimens and of a syngeneic glioma model express CCR2 to varying extents. Using a -deficient strain for glioma inoculation revealed a 30% reduction of TAMs intratumorally. This diminished immune cell infiltration occurred with augmented tumor volumes likely based on increased cell proliferation. Remaining TAMs in mice showed comparable surface marker expression patterns in comparison to wildtype mice, but expression levels of inflammatory transcription factors (, , ) and cytokines (, , ) were considerably affected. Furthermore, we demonstrated an impact on blood vessel integrity, while vascularization of tumors appeared similar between mouse strains. The higher stability and attenuated leakiness of the tumor vasculature imply improved sustenance of glioma tissue in mice. Additionally, despite TAMs residing in the perivascular niche in mice, their pro-angiogenic activity was reduced by the downregulation of . In conclusion, lacking CCR2 solely on tumor microenvironmental cells leads to enhanced tumor progression, whereby high numbers of TAMs infiltrate gliomas independently of the CCR2/CCL2 signal.

摘要

多形性胶质母细胞瘤(GBM)显示出肿瘤相关巨噬细胞(TAM)的大量涌入。CCR2/CCL2通路被认为是招募TAM的相关信号,并已被建议作为恶性胶质瘤的治疗靶点。我们发现,人类GBM标本和同基因胶质瘤模型中的TAM在不同程度上表达CCR2。使用CCR2缺陷株接种胶质瘤显示肿瘤内TAM减少了30%。这种免疫细胞浸润的减少伴随着肿瘤体积的增大,这可能是由于细胞增殖增加所致。与野生型小鼠相比,CCR2缺陷小鼠中剩余的TAM显示出相当的表面标志物表达模式,但炎症转录因子(NF-κB、STAT3、IRF8)和细胞因子(IL-6、IL-10、TNF-α)的表达水平受到显著影响。此外,我们证明了对血管完整性的影响,而小鼠品系之间肿瘤的血管生成似乎相似。肿瘤血管系统更高的稳定性和减弱的渗漏性意味着CCR2缺陷小鼠中胶质瘤组织的营养供应得到改善。此外,尽管CCR2缺陷小鼠中的TAM存在于血管周围微环境中,但它们的促血管生成活性因VEGF的下调而降低。总之,仅肿瘤微环境细胞缺乏CCR2会导致肿瘤进展增强,由此大量TAM独立于CCR2/CCL2信号浸润胶质瘤。

相似文献

1
CCR2 of Tumor Microenvironmental Cells Is a Relevant Modulator of Glioma Biology.肿瘤微环境细胞的CCR2是胶质瘤生物学的相关调节因子。
Cancers (Basel). 2020 Jul 13;12(7):1882. doi: 10.3390/cancers12071882.
2
CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages.CCL2/CCR2轴通过募集和重编程肿瘤相关巨噬细胞促进涎腺腺样囊性癌的进展。
Front Oncol. 2019 Apr 9;9:231. doi: 10.3389/fonc.2019.00231. eCollection 2019.
3
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.通过 CCL2/CCR2 信号靶向肿瘤浸润巨噬细胞作为一种治疗肝细胞癌的策略。
Gut. 2017 Jan;66(1):157-167. doi: 10.1136/gutjnl-2015-310514. Epub 2015 Oct 9.
4
VEGF as a modulator of the innate immune response in glioblastoma.VEGF 作为胶质母细胞瘤固有免疫反应的调节剂。
Glia. 2018 Jan;66(1):161-174. doi: 10.1002/glia.23234. Epub 2017 Sep 26.
5
Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors.脑肿瘤中,局部的小胶质细胞而非外周的巨噬细胞促进血管生成,并且是替代性促血管生成因子的来源。
Acta Neuropathol. 2016 Mar;131(3):365-78. doi: 10.1007/s00401-015-1529-6. Epub 2015 Dec 30.
6
CYP4X1 Inhibition by Flavonoid CH625 Normalizes Glioma Vasculature through Reprogramming TAMs via CB2 and EGFR-STAT3 Axis.黄酮类化合物 CH625 通过 CB2 和 EGFR-STAT3 轴重编程 TAMs 抑制 CYP4X1 使胶质瘤血管正常化。
J Pharmacol Exp Ther. 2018 Apr;365(1):72-83. doi: 10.1124/jpet.117.247130. Epub 2018 Feb 1.
7
CCL2/CCR2 signaling pathway in glioblastoma multiforme.多形性胶质母细胞瘤中的CCL2/CCR2信号通路。
Neurochem Int. 2017 Feb;103:1-7. doi: 10.1016/j.neuint.2016.12.013. Epub 2016 Dec 24.
8
Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas.胶质瘤中肿瘤相关巨噬细胞(TAM)活性的靶向治疗选择
Curr Neuropharmacol. 2023;21(3):457-470. doi: 10.2174/1570159X20666220120120203.
9
C-C motif chemokine ligand 2/C-C receptor 2 is associated with glioma recurrence and poor survival.C-C基序趋化因子配体2/C-C受体2与胶质瘤复发及生存期短相关。
Exp Ther Med. 2021 Jun;21(6):564. doi: 10.3892/etm.2021.9996. Epub 2021 Mar 26.
10
Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities.胶质瘤中的肿瘤相关巨噬细胞——基本见解与治疗机遇
Cancers (Basel). 2022 Mar 4;14(5):1319. doi: 10.3390/cancers14051319.

引用本文的文献

1
Gene function revealed at the moment of stochastic gene silencing.基因功能在随机基因沉默之时得以揭示。
Commun Biol. 2025 Jan 19;8(1):88. doi: 10.1038/s42003-025-07530-0.
2
Key Cell-in-Cell Related Genes are Identified by Bioinformatics and Experiments in Glioblastoma.通过生物信息学和实验鉴定胶质母细胞瘤中关键的细胞中细胞相关基因。
Cancer Manag Res. 2024 Sep 5;16:1109-1130. doi: 10.2147/CMAR.S475513. eCollection 2024.
3
Microglia and macrophages in glioblastoma: landscapes and treatment directions.胶质母细胞瘤中的小胶质细胞和巨噬细胞:现状与治疗方向

本文引用的文献

1
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.CCR2 抑制减少肿瘤髓系细胞,并揭示检查点抑制剂的作用以减缓耐药性小鼠脑胶质瘤的进展。
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1129-1138. doi: 10.1073/pnas.1910856117. Epub 2019 Dec 26.
2
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.干扰素-γ 在肿瘤免疫监视或逃逸的十字路口。
Front Immunol. 2018 May 4;9:847. doi: 10.3389/fimmu.2018.00847. eCollection 2018.
3
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.
Mol Oncol. 2024 Dec;18(12):2906-2926. doi: 10.1002/1878-0261.13657. Epub 2024 May 7.
4
CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.CCR2 和 CCR5 双重抑制调节胶质母细胞瘤中的免疫抑制性髓系微环境,并与抗 PD-1 治疗协同作用。
Oncoimmunology. 2024 Apr 4;13(1):2338965. doi: 10.1080/2162402X.2024.2338965. eCollection 2024.
5
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia.靶向 CCL2/CCR2 信号通路克服急性髓系白血病中 MEK 抑制剂耐药性。
Clin Cancer Res. 2024 May 15;30(10):2245-2259. doi: 10.1158/1078-0432.CCR-23-2654.
6
Tumor-associated macrophage-related strategies for glioma immunotherapy.用于神经胶质瘤免疫治疗的肿瘤相关巨噬细胞相关策略。
NPJ Precis Oncol. 2023 Aug 19;7(1):78. doi: 10.1038/s41698-023-00431-7.
7
Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.胶质母细胞瘤相关的小胶质细胞/巨噬细胞(GAMs):肿瘤微环境中的免疫功能及其对免疫治疗的影响。
Front Immunol. 2023 Mar 9;14:1123853. doi: 10.3389/fimmu.2023.1123853. eCollection 2023.
8
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma.针对小胶质细胞代谢重编程与免疫检查点阻断疗法联合治疗胶质母细胞瘤。
Cancer Discov. 2023 Apr 3;13(4):974-1001. doi: 10.1158/2159-8290.CD-22-0455.
9
Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.目前对弥漫性中线胶质瘤的看法,以及与胶质母细胞瘤相比,其免疫微环境的不同作用。
J Neuroinflammation. 2022 Nov 19;19(1):276. doi: 10.1186/s12974-022-02630-8.
10
Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogramming.几丁质酶 3 样蛋白 1 通过 NF-κB 信号通路和肿瘤微环境重编程促进胶质瘤的进展。
Theranostics. 2022 Oct 3;12(16):6989-7008. doi: 10.7150/thno.75069. eCollection 2022.
IFNAR1 控制髓系来源抑制细胞中 PD-L1 表达的自分泌 I 型 IFN 调节。
J Immunol. 2018 Jul 1;201(1):264-277. doi: 10.4049/jimmunol.1800129. Epub 2018 May 11.
4
When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.当免疫细胞“叛变”——胶质瘤中的肿瘤相关小胶质细胞/巨噬细胞。
Int J Mol Sci. 2018 Feb 1;19(2):436. doi: 10.3390/ijms19020436.
5
Microvascular Mural Cell Organotypic Heterogeneity and Functional Plasticity.微血管壁细胞的器官型异质性和功能可塑性。
Trends Cell Biol. 2018 Apr;28(4):302-316. doi: 10.1016/j.tcb.2017.12.002. Epub 2018 Jan 5.
6
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.用于癌症免疫治疗的PD-1和PD-L1检查点信号抑制:机制、联合应用及临床结果
Front Pharmacol. 2017 Aug 23;8:561. doi: 10.3389/fphar.2017.00561. eCollection 2017.
7
The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease.小胶质细胞/巨噬细胞在脑癌肿瘤进展和转移疾病中的作用。
Front Biosci (Landmark Ed). 2017 Jun 1;22(10):1805-1829. doi: 10.2741/4573.
8
Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma.表达高水平CD45的髓样细胞与胶质瘤中一种独特的活化表型相关。
Immunol Res. 2017 Jun;65(3):757-768. doi: 10.1007/s12026-017-8915-1.
9
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.胶质母细胞瘤中肿瘤相关巨噬细胞的细胞和分子特征
Cancer Res. 2017 May 1;77(9):2266-2278. doi: 10.1158/0008-5472.CAN-16-2310. Epub 2017 Feb 24.
10
Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.使用CCL2中和抗体阻断CCL2-CCR2轴是小鼠模型中肝细胞癌的有效治疗方法。
Mol Cancer Ther. 2017 Feb;16(2):312-322. doi: 10.1158/1535-7163.MCT-16-0124. Epub 2016 Dec 15.